品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|---|
阿拉丁 | I129780-10mg | 10mg | 现货 | 1127442-82-3 |
IWR-1,Wnt /β-catenin信号传导抑制剂 IWR-1 |
≥98% |
|
|
阿拉丁 | I129780-50mg | 50mg | 现货 | 1127442-82-3 |
IWR-1,Wnt /β-catenin信号传导抑制剂 IWR-1 |
≥98% |
|
|
阿拉丁 | I129780-5mg | 5mg | 现货 | 1127442-82-3 |
IWR-1,Wnt /β-catenin信号传导抑制剂 IWR-1 |
≥98% |
|
|
阿拉丁 | I408301-1ml | 1ml | 期货,请咨询 | 1127442-82-3 |
IWR-1-endo IWR-1-endo |
10mM in DMSO |
|
|
麦克林 | I872800-5mg | 5mg | 订前询问 | 1127442-82-3 |
IWR-1-endo IWR-1-endo |
0.99 |
|
|
罗恩 | R022049-50mg | 50mg | 5~7个工作日 | 1127442-82-3 |
el-4-[(3aR,4S,7R,7aS)-1,3,3... IWR-1-endo |
99% |
|
|
罗恩 | R022049-10mg | 10mg | 5~7个工作日 | 1127442-82-3 |
el-4-[(3aR,4S,7R,7aS)-1,3,3... IWR-1-endo |
99% |
|
|
MARY | MR1331510-10mg | 10mg | 订前咨询 | 1127442-82-3 |
el-4-[(3aR,4S,7R,7aS)-1,3,3... IWR-1-endo |
99% |
|
|
MARY | MR1331510-50mg | 50mg | 订前咨询 | 1127442-82-3 |
el-4-[(3aR,4S,7R,7aS)-1,3,3... IWR-1-endo |
99% |
|
|
源叶 | S80108-5mg | 5mg | 现货 | 1127442-82-3 |
IWR-1-endo IWR-1-endo |
99% |
|
|
源叶 | S80108-10mg | 10mg | 现货 | 1127442-82-3 |
IWR-1-endo IWR-1-endo |
99% |
|
|
源叶 | S80108-25mg | 25mg | 现货 | 1127442-82-3 |
IWR-1-endo IWR-1-endo |
99% |
|
|
源叶 | S80108-100mg | 100mg | 期货,请咨询 | 1127442-82-3 |
IWR-1-endo IWR-1-endo |
99% |
|
|
源叶 | T95112-1ml | 1ml | 期货,请咨询 | 1127442-82-3 |
IWR-1-endo IWR-1-endo |
10mM in DMSO |
|
|
毕得 | BD256999-5mg | 5mg | 现货 | 1127442-82-3 |
4-((3aR,4S,7R,7aS)-rel-1,3-二... rel-4-((3aR,4S,7R,7aS)-1,3-D... |
98% |
|
|
毕得 | BD256999-10mg | 10mg | 现货 | 1127442-82-3 |
4-((3aR,4S,7R,7aS)-rel-1,3-二... rel-4-((3aR,4S,7R,7aS)-1,3-D... |
98% |
|
|
毕得 | BD256999-1mg | 1mg | 现货 | 1127442-82-3 |
4-((3aR,4S,7R,7aS)-rel-1,3-二... rel-4-((3aR,4S,7R,7aS)-1,3-D... |
98% |
|
|
梯希爱 | I1167-25MG | 25MG | 现货 | 1127442-82-3 |
el-4-[(3aR,4S,7R,7aS)-1,3-二... IWR-1 |
95.0% |
|
|
百灵威 | 1189408-5MG | 5MG | 1-3天 | 1127442-82-3 |
IWR-1 IWR-1, 98%, a tankyrase inhi... |
98% |
|
|
百灵威 | 1189408-10MG | 10MG | 1-3天 | 1127442-82-3 |
IWR-1 IWR-1, 98%, a tankyrase inhi... |
98% |
|
|